Studies of neuroendocrine carcinomas (NEC)

Description

The Nordic NEC study has become highly recognized worldwide. The Nordic Neuroendocrine Tumor Group, led by Tiensuu Janson continues to perform research on this tumor group.

In 2015 a group of international pathologists visited Uppsala to go through the tumor samples collected from patients in the Nordic NEC registry with the aim to develop a new classification. A clinical trial with a new combination of drugs (temozolomide and everolimus) for the subgroup of patients with a lower Ki67 has started and is recruiting patients from the Nordic countries.

Further studies on this patient group are ongoing to evaluate the expression of tumor biomarkers in tissue and to evaluate the impact of surgery on survival for NEC patients.